ethylene glycol tert-butyl ether

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethylene glycol tert-butyl ether
• 英文别名: ethylene glycol t-butyl ether；Ethane-1,2-diol;2-methyl-2-[(2-methylpropan-2-yl)oxy]propane
• 化学式: C₂H₆O₂*C₈H₁₈O
• 分子量: 192.299
• InChiKey: NMGMAJJRWFGENL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.57
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethylene glycol tert-butyl ether 生成 N-succinimidyl 2-tert-butoxyethyl carbonate
  参考文献：
  名称：

  LISSENCEPHALY THERAPEUTIC AGENT

  摘要：

  公开号：

  EP2647386B1

文献信息

• [EN] ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF<br/>[FR] DERIVE D'ALPHA-CETOAMIDE, SON PROCEDE DE PRODUCTION ET D'UTILISATION
  申请人：SENJU PHARMA CO

  公开号：WO2005056519A1

  公开（公告）日：2005-06-23

  The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optionally substituted by a phenyl; and R3 is a lower alkyl optionally substituted by a halogen, a lower alkoxy or a phenyl, or a fused polycyclic hydrocarbon group), which is well absorbed orally, exhibits durability of good blood level and has potent calpain inhibitory activity.

  本发明提供了一种化合物，其化学式表示为（I）：（插入化学式）（其中R1是由低烷基取代的低烷氧基或杂环基，或者是杂环基；R2是可选择地由苯基取代的低烷基；R3是可选择地由卤素、低烷氧基或苯基取代的低烷基，或者是融合的多环碳氢基），该化合物在口服后被很好地吸收，表现出良好的血液水平持久性，并具有强大的钙蛋白酶抑制活性。
• COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER
  申请人：OSAKA CITY UNIVERSITY

  公开号：US20190314320A1

  公开（公告）日：2019-10-17

  The present invention provides a means for treating and/or preventing peripheral nerve disorder by facilitating regeneration of peripheral nerves. Specifically, the present invention provides a composition for treating and/or preventing peripheral nerve disorder comprising a compound represented by the general formula (I): wherein R 1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): R 4 O—R 5  m (IIa) wherein R 4 is lower alkyl, R 5 is lower alkylene, and m is an integer of 1 to 6; R 2 is lower alkyl optionally substituted with phenyl; and R 3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

  本发明提供了一种治疗和/或预防外周神经障碍的方法，通过促进外周神经再生。具体地，本发明提供了一种用于治疗和/或预防外周神经障碍的组合物，包括由通式（I）表示的化合物： 其中R1为与低烷氧基取代的低烷基，与杂环基取代的低烷基，杂环基，或由式（IIa）表示的基团： R4O—R5m（IIa） 其中R4为低烷基，R5为低烷基烯，m为1至6的整数； R2为可选择地取代苯基的低烷基；和 R3为可选择地取代卤素，低烷氧基，或苯基的低烷基；缩合多环碳氢化合物；或氢。
• FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM
  申请人：SHOWA DENKO K.K.

  公开号：US20190084911A1

  公开（公告）日：2019-03-21

  The present invention relates to a fluorine-containing ether compound represented by Formula (1), R 1 —R 2 —CH 2 —R 3 —CH 2 —R 4 (1). (In Formula (1), R 1 is an end group including an organic group having at least one double bond or triple bond, R 2 is a divalent linking group bonded to R 1 by etheric oxygen, R 3 is a perfluoropolyether chain, R 4 is an end group having two or three polar groups with each polar group being bonded to different carbon atoms, and the carbon atoms, to which the polar groups are bonded, being bonded to each other via a linking group including carbon atoms to which the polar groups are not bonded.)

  该发明涉及一种由化学式（1）表示的含氟醚化合物，R1—R2—CH2—R3—CH2—R4（1）。在化学式（1）中，R1是包括至少一个双键或三键的有机基团的末端基团，R2是通过醚氧与R1相结合的二价连接基团，R3是全氟聚醚链，R4是具有两个或三个极性基团的末端基团，每个极性基团与不同的碳原子结合，而与极性基团结合的碳原子通过包括极性基团未结合的碳原子的连接基团相互结合。
• FARNESOID X RECEPTOR AGONISTS
  申请人：NAVAS Frank

  公开号：US20080096921A1

  公开（公告）日：2008-04-24

  The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.

  本发明提供了新型的取代异噁唑化合物、药物组合物、治疗用途和制备方法。
• [EN] PROCESS FOR THE PREPARATION OF BOSENTAN<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE BOSENTAN
  申请人：CADILA PHARMACEUTICALS LTD

  公开号：WO2013186706A1

  公开（公告）日：2013-12-19

  The present invention relates to a process for the preparation of Bosentan (Formula 1) or pharmaceutically acceptable salts or hydrates thereof which results the product substantially free of impurities like ethylene glycol bis-sulfonamide dimer and 6-hydroxy sulfonamide. The process according to present invention is also producing Bosentan sodium and Bosentan ammonium which gives Bosentan or pharmaceutically acceptable salts or hydrates thereof in improved yield and quality as compared to prior art processes.

  本发明涉及一种制备波生坦（化学式1）或其药用可接受盐或水合物的方法，该方法使得产品基本上不含有乙二醇双磺酰胺二聚体和6-羟基磺酰胺等杂质。根据本发明的方法还生产波生坦钠和波生坦铵，与先前的工艺相比，该方法产量和质量均得到了改善。